[Autoimmune hemolytic anemia induced by alpha-interferon therapy in a case of IgG-kappa type multiple myeloma].
A 47-year-old male case of IgG-kappa type multiple myeloma was treated with VMCP and recombinant human alpha-interferon (IFN-alpha 2a). The direct Coombs test was positive before treatment. Hemolytic anemia associated with massive hematuria was observed during the administration of 9 million IU IFN-alpha 2a per day for 2 weeks. The hemolytic symptoms rapidly improved after withdrawal of IFN-alpha 2a. This clinical course suggests that IFN-alpha as an immunomodulator was responsible for the progression of autoimmune hemolytic anemia in a case of multiple myeloma.
Onoda
K
K
Department of Hematology, Niigata City General Hospital.
Takai
K
K
Sanada
M
M
Aoki
S
S
Watanabe
T
T
D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D007145:Immunoglobulin kappa-Chains / Q000032:analysis*; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D011994:Recombinant Proteins / Q000009:adverse effects
D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains; D016898:Interferon-alpha; D011994:Recombinant Proteins